Stellaromics

About Stellaromics

Founded in 2022 and headquartered in Boston, Stellaromics is revolutionizing biomedical research with its proprietary technology, unraveling complex 3D transcription and translation patterns within native biological tissue. At the forefront of their innovation is STARmap (Spatially-resolved Transcript Amplicon Readout mapping), their flagship product. STARmap empowers researchers to uncover gene expression patterns within intact tissue, facilitating the pinpointing of treatment targets and bolstering biomedical investigations. Stellaromics is currently in the advanced stages of developing its Pyxa suite of products, meticulously crafted to empower researchers and clinicians in the creation of intricate cellular maps, thereby amplifying our comprehension of various diseases.